Eloxx Pharmaceuticals annual ebitda
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals EBITDA Growth & History (ELOX)
Eloxx Pharmaceuticals's calculated EBITDA was −$6.4M for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$6.4M | −$4.0M | — |
| 2024 | 2024-12-31 | −$2.4M | $14.7M | — |
| 2023 | 2023-12-31 | −$17.2M | $17.2M | — |
| 2022 | 2022-12-31 | −$34.3M | $31.6M | — |
| 2021 | 2021-12-31 | −$65.9M | −$32.5M | — |
| 2020 | 2020-12-31 | −$33.4M | $17.1M | — |
| 2019 | 2019-12-31 | −$50.5M | −$3.1M | — |
| 2018 | 2018-12-31 | −$47.3M | −$27.0M | — |
| 2017 · Dec 31 | 2017-12-31 | −$20.4M | −$10.5M | — |
| 2017 · Jun 30 | 2017-06-30 | −$4.5M | $6.6M | — |
| 2016 · Dec 31 | 2016-12-31 | −$9.8M | −$3.6M | — |
| 2016 · Jun 30 | 2016-06-30 | −$11.1M | $6.8M | — |
| 2015 · Dec 31 | 2015-12-31 | −$6.3M | — | — |
| 2015 · Jun 30 | 2015-06-30 | −$17.9M | −$9.1M | — |
| 2014 | 2014-06-30 | −$8.8M | −$4.4M | — |
| 2013 | 2013-06-30 | −$4.4M | $796,634 | — |
| 2012 | 2012-06-30 | −$5.2M | $2.6M | — |
| 2011 | 2011-06-30 | −$7.8M | −$3.1M | — |
| 2010 | 2010-06-30 | −$4.7M | — | — |
Eloxx Pharmaceuticals quarterly ebitda
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$4.5M | −$2.9M | — |
| Q1 2026 | 2026-03-31 | −$3.7M | −$2.5M | — |
| Q2 2025 | 2025-06-30 | −$1.6M | — | — |
| Q1 2025 | 2025-03-31 | −$1.2M | — | — |
| Q4 2023 | 2023-12-31 | −$4.0M | $2.1M | — |
| Q3 2023 | 2023-09-30 | −$3.6M | $3.5M | — |
| Q2 2023 | 2023-06-30 | −$4.1M | $6.1M | — |
| Q1 2023 | 2023-03-31 | −$5.5M | $5.5M | — |
| Q4 2022 | 2022-12-31 | −$6.0M | $5.6M | — |
| Q3 2022 | 2022-09-30 | −$7.1M | $3.1M | — |
| Q2 2022 | 2022-06-30 | −$10.3M | $25.4M | — |
| Q1 2022 | 2022-03-31 | −$10.9M | −$2.5M | — |
| Q4 2021 | 2021-12-31 | −$11.6M | −$5.8M | — |
| Q3 2021 | 2021-09-30 | −$10.2M | −$3.9M | — |
| Q2 2021 | 2021-06-30 | −$35.7M | −$28.1M | — |
| Q1 2021 | 2021-03-31 | −$8.4M | $5.3M | — |
| Q4 2020 | 2020-12-31 | −$5.8M | $5.7M | — |
| Q3 2020 | 2020-09-30 | −$6.3M | $6.5M | — |
| Q2 2020 | 2020-06-30 | −$7.6M | $6.7M | — |
| Q1 2020 | 2020-03-31 | −$13.7M | −$1.8M | — |
| Q4 2019 | 2019-12-31 | −$11.5M | $2.5M | — |
| Q3 2019 | 2019-09-30 | −$12.8M | −$1.5M | — |
| Q2 2019 | 2019-06-30 | −$14.3M | −$776,000 | — |
| Q1 2019 | 2019-03-31 | −$11.9M | −$3.4M | — |
| Q4 2018 | 2018-12-31 | −$14.0M | −$3.5M | — |
| Q3 2018 | 2018-09-30 | −$11.3M | −$7.3M | — |
| Q2 2018 | 2018-06-30 | −$13.5M | −$10.3M | — |
| Q1 2018 · Mar 31 | 2018-03-31 | −$8.5M | −$5.9M | — |
| Q4 2017 | 2017-12-31 | −$10.6M | −$9.1M | — |
| Q1 2018 · Sep 30 | 2017-09-30 | −$4.0M | −$1.8M | — |
| Q4 2017 | 2017-06-30 | −$3.2M | −$1.8M | — |
| Q1 2017 · Mar 31 | 2017-03-31 | −$2.6M | $2.2M | — |
| Q4 2016 | 2016-12-31 | −$1.5M | $2.2M | — |
| Q1 2017 · Sep 30 | 2016-09-30 | −$2.2M | −$1.1M | — |
| Q4 2016 | 2016-06-30 | −$1.4M | −$502,801 | — |
| Q1 2016 · Mar 31 | 2016-03-31 | −$4.9M | −$3.7M | — |
| Q4 2015 | 2015-12-31 | −$3.7M | $7.0M | — |
| Q1 2016 · Sep 30 | 2015-09-30 | −$1.1M | $4.0M | — |
| Q4 2015 | 2015-06-30 | −$880,909 | $2.7M | — |
| Q3 2015 | 2015-03-31 | −$1.2M | $857,003 | — |
| Q2 2015 | 2014-12-31 | −$10.7M | −$9.2M | — |
| Q1 2015 | 2014-09-30 | −$5.1M | −$3.4M | — |
| Q4 2014 | 2014-06-30 | −$3.6M | −$2.6M | — |
| Q3 2014 | 2014-03-31 | −$2.0M | −$1.1M | — |
| Q2 2014 | 2013-12-31 | −$1.5M | −$277,278 | — |
| Q1 2014 | 2013-09-30 | −$1.7M | −$495,355 | — |
| Q4 2013 | 2013-06-30 | −$968,308 | $525,684 | — |
| Q3 2013 | 2013-03-31 | −$972,783 | $69,433 | — |
| Q2 2013 | 2012-12-31 | −$1.2M | $161,272 | — |
| Q1 2013 | 2012-09-30 | −$1.2M | $40,245 | — |
| Q4 2012 | 2012-06-30 | −$1.5M | $1.3M | — |
| Q3 2012 | 2012-03-31 | −$1.0M | $289,342 | — |
| Q2 2012 | 2011-12-31 | −$1.4M | $75,554 | — |
| Q1 2012 | 2011-09-30 | −$1.2M | $948,273 | — |
| Q4 2011 | 2011-06-30 | −$2.8M | — | — |
| Q3 2011 | 2011-03-31 | −$1.3M | — | — |
| Q2 2011 | 2010-12-31 | −$1.5M | — | — |
| Q1 2011 | 2010-09-30 | −$2.2M | — | — |
Eloxx Pharmaceuticals ebitda trends
Over the last five fiscal years, Eloxx Pharmaceuticals's ebitda increased from −$33.4M to −$6.4M, a change of $26.9M. The latest reported quarter, Q2 2026, shows −$4.5M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...
